Skip to main content

Pulmonx Corporation (LUNG)

NASDAQ: LUNG · IEX Real-Time Price · USD
39.36 -0.25 (-0.63%)
Sep 24, 2021 4:00 PM EDT - Market closed
Market Cap1.44B
Revenue (ttm)41.89M
Net Income (ttm)-37.58M
Shares Out36.04M
EPS (ttm)-1.39
PE Ration/a
Forward PE28.33
Dividendn/a
Ex-Dividend Daten/a
Volume255,033
Open39.27
Previous Close39.61
Day's Range38.87 - 39.79
52-Week Range35.81 - 69.48
Betan/a
AnalystsBuy
Price Target55.67 (+41.4%)
Est. Earnings DateNov 2, 2021

About LUNG

Pulmonx Corporation, a medical technology company, designs, develops, manufactures, and markets minimally invasive medical devices for the diagnosis and treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also prov...

IndustryHealth Care Equipment & Supplies
IPO DateOct 1, 2020
Employees220
Stock ExchangeNASDAQ
Ticker SymbolLUNG
Full Company Profile

Financial Performance

In 2020, Pulmonx's revenue was $32.73 million, an increase of 0.42% compared to the previous year's $32.60 million. Losses were -$32.23 million, 55.7% more than in 2019.

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for Pulmonx stock is "Buy." The 12-month stock price forecast is 55.67, which is an increase of 41.44% from the latest price.

Price Target
$55.67
(41.44% upside)
Analyst Consensus: Buy

News

Chief Financial Officer Of Pulmonx Makes $224.56 Thousand Sale

Derrick Sung, Chief Financial Officer at Pulmonx (NASDAQ:LUNG), made a large insider sell on September 21, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exch...

2 days ago - Benzinga

Pulmonx Announces Two Additional Significant Blue Cross Blue Shield Plans Now Provide Coverage for Severe Emphysema/C...

REDWOOD CITY, Calif.--(BUSINESS WIRE)---- $LUNG #COPD--Pulmonx Announces BCBS of Michigan and Horizon BCBS of New Jersey Issue Coverage Policies Providing Coverage for Treatment with the Zephyr® Valve

3 days ago - Business Wire

3 Healthcare Stocks That Might Skyrocket When COVID Is Over

Stocks of biotech companies fighting COVID-19 have been great investments over the last two years. What stocks might zoom higher when the pandemic is over?

Other symbols:AXSMVRTX
2 weeks ago - The Motley Fool

Pulmonx to Present at Upcoming September Investor Conferences

REDWOOD CITY, Calif., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) today announced the company will be participating in fireside chats at two upcoming virtual investo...

4 weeks ago - GlobeNewsWire

Pulmonx Announces Anthem Blue Cross Blue Shield Now Provides Coverage for Severe COPD/Emphysema Treatment

REDWOOD CITY, Calif.--(BUSINESS WIRE)---- $LUNG #COPD--Positive Coverage Policy Gives Additional 34 Million People Access to Treatment with the Zephyr® Valve, a Minimally Invasive Treatment Option

1 month ago - Business Wire

Pulmonx Reports Second Quarter 2021 Financial Results

REDWOOD CITY, Calif., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for severe lung disease, today r...

1 month ago - GlobeNewsWire

Pulmonx Welcomes Two New Board Members, Adding Expertise in Health Technology, Consumer Marketing, and Integrated Hea...

Alissa Hsu Lynch and Tiffany Sullivan join the Pulmonx Board of Directors Alissa Hsu Lynch and Tiffany Sullivan join the Pulmonx Board of Directors

1 month ago - GlobeNewsWire

Pulmonx Announces Long-Term Follow-Up Data Confirming Significant Benefits of Zephyr Valve for Patients with Severe C...

REDWOOD CITY, Calif.--(BUSINESS WIRE)-- #COPD--Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for severe lung disease, today announced the publication o...

1 month ago - Business Wire

Pulmonx to Report Second Quarter 2021 Financial Results on August 3, 2021

REDWOOD CITY, Calif., July 20, 2021 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will re...

2 months ago - GlobeNewsWire

Pulmonx Reports First Quarter 2021 Financial Results

REDWOOD CITY, Calif., May 04, 2021 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for severe lung disease, today re...

4 months ago - GlobeNewsWire

Pulmonx to Report First Quarter 2021 Financial Results on May 4, 2021

REDWOOD CITY, Calif., April 20, 2021 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will r...

5 months ago - GlobeNewsWire

DraftKings, H&R Block, Novartis and More Wednesday Afternoon Analyst Calls

With the trading day more than halfway over, the broad markets were pushing higher yet again.

6 months ago - 24/7 Wall Street

Pulmonx Reports Fourth Quarter and Full Year 2020 Financial Results

REDWOOD CITY, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today reporte...

6 months ago - GlobeNewsWire

Pulmonx to Report Fourth Quarter and Full Year 2020 Financial Results on March 2, 2021

REDWOOD CITY, Calif., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will re...

7 months ago - GlobeNewsWire

Pulmonx Welcomes Two New Members to Its Board of Directors, Adding Expertise in Consumer Marketing and Medical Device...

Georgia Garinois-Melenikiotou and Thomas W. Burns Joined the Pulmonx Board in October in Connection with the Company's Initial Public Offering Georgia Garinois-Melenikiotou and Thomas W. Burns Joined th...

9 months ago - GlobeNewsWire

Over 20,000 Patients Treated with the Non-Surgical Zephyr Valve for Severe Emphysema, a Form of COPD

The Zephyr Valve Helps COPD/Emphysema Patients Breathe Easier Without the Risk of Major Surgery 1

9 months ago - GlobeNewsWire

Pulmonx Reports Third Quarter 2020 Financial Results

REDWOOD CITY, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a commercial-stage medical technology company that provides minimally invasive treatment for patie...

10 months ago - GlobeNewsWire

Pulmonx to Present at Upcoming Investor Conferences

REDWOOD CITY, Calif., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) today announced the company will be participating in two upcoming virtual investor conferences.

10 months ago - GlobeNewsWire

Pulmonx Announces Additional 16 Million Covered Lives for The Zephyr® Valve, a Minimally Invasive Treatment Option fo...

Positive Coverage Policy from Health Care Service Corporation (HCSC) Covers Blue Cross Blue Shield Members in Illinois, Montana, New Mexico, Oklahoma and Texas Positive Coverage Policy from Health Care ...

10 months ago - GlobeNewsWire

Pulmonx to Report Third Quarter 2020 Financial Results on November 10, 2020

REDWOOD CITY, Calif., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will re...

11 months ago - GlobeNewsWire

Last Week's Notable Insider Buys: Element Solutions, Selecta Biosciences And More

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it. So insider buying can ...

Other symbols:ESISELBAVOIMNM
11 months ago - Benzinga

Pulmonx Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additi...

REDWOOD CITY, Calif., Oct. 05, 2020 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a commercial-stage medical technology company that provides a minimally invasive treatment for pat...

11 months ago - GlobeNewsWire

Pulmonx: Assessing The IPO

Pulmonx: Assessing The IPO

11 months ago - Seeking Alpha

Pulmonx shares soar 118% in trading debut

Shares of Pulmonx, a maker of treatments for lung diseases including emphysema, rose 118% in their trading debut Thursday, after the company's initial public offering priced above range. The deal priced...

11 months ago - Market Watch

Pulmonx prices IPO at $19 a share, above proposed price range

Pulmonx, a maker of treatments for lung diseases including emphysema, priced its initial public offering at $19 a share, above its proposed price range of $17 to $18.

11 months ago - Market Watch